SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Jemal A, Siegel R, Ward E, et al. Cancer statistics 2008. CA Cancer J Clin. 2008; 58: 71-96.
  • 2
    Slamon DJ, Clark GM, Wong SG, et al. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science. 1987; 235: 177-182.
  • 3
    Paik S, Hazan R, Fisher ER, et al. Pathologic findings from the National Surgical Adjuvant Breast and Bowel Project: prognostic significance of erbB-2 protein overexpression in primary breast cancer. J Clin Oncol. 1990; 8: 103-112.
  • 4
    Press M, Bernstein L, Thomas P, et al. HER-2/neu gene amplification by fluorescence in situ hybridization: evaluation of archival specimens and utility as a marker of poor prognosis in node-negative invasive breast carcinomas. J Clin Oncol. 1997; 15: 2894-2904.
  • 5
    Sjogren S, Inganas M, Lindgren A, Holmberg L, Bergh J. Prognostic and predictive value of c-erbB-2 overexpression in primary breast cancer, alone and in combination with other prognostic markers. J Clin Oncol. 1998; 16: 462-469.
  • 6
    Owens MA, Horten BC, Da Silva MM. HER2 amplification ratios by fluorescence in situ hybridization and correlation with immunohistochemistry in a cohort of 6556 breast cancer tissues. Clin Breast Cancer. 2004; 5: 63-69.
  • 7
    Perez EA, Romond EH, Suman V, et al. Updated results of the combined analysis of NCCTG N9831 and NSABP B-31 adjuvant chemotherapy with/without trastuzumab in patients with HER2-positive breast cancer [abstract]. J Clin Oncol. 2007; 25( 18S): 6s. Abstract 512.
  • 8
    Smith I, Procter M, Gelber RD, et al. Two-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial. Lancet. 2007; 369: 29-36.
  • 9
    Slamon D, Eiermann W, Robert N, et al; on behalf of the BCIRG 006 Investigators. Phase III trial comparing AC-T with AC-TH and with TCH in the adjuvant treatment of HER2-positive early breast cancer patients: second interim efficacy analysis [abstract]. Breast Cancer Res Treat. 2006: 100( suppl 1). Abstract 53.
  • 10
    Piccart-Gebhart MJ, Procter M, Leyland-Jones B, et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med. 2005; 353: 1659-1672.
  • 11
    Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med. 2001; 344: 783-792.
  • 12
    Esteva FJ, Hortobagyi GN. Can early response assessment guide neoadjuvant chemotherapy in early-stage breast cancer? J Natl Cancer Inst. 2008; 100: 521-523.
  • 13
    Rastogi P, Anderson SJ, Bear HD, et al. Preoperative chemotherapy: updates of National Surgical Adjuvant Breast and Bowel Project protocols B-18 and B-27. J Clin Oncol. 2008; 10: 778-785.
  • 14
    Wolff AC, Davidson NE. Primary systemic therapy in operable breast cancer. J Clin Oncol. 2000; 18: 1558-1569.
  • 15
    Van der Hage JA, Van de Velde CJ, Julien JP, et al. Preoperative chemotherapy in primary operable breast cancer: results from the European Organization for Research and Treatment of Cancer trial 10902. J Clin Oncol. 2001; 19: 4224-4237.
  • 16
    Mauri D, Pavlidis N, Ioannidis JP. Neoadjuvant versus adjuvant systemic treatment in breast cancer: a meta-analysis. J Natl Cancer Inst. 2005; 97: 188-194.
  • 17
    Fisher B, Mamounas EP. Preoperative chemotherapy: a model for studying the biology and therapy of primary breast cancer. J Clin Oncol. 1995; 13: 537-540.
  • 18
    Londero V, Bazzocchi M, Del Frate C, et al. Locally advanced breast cancer: comparison of mammography, sonography and MR imaging in evaluation of residual disease in women receiving neoadjuvant chemotherapy. Eur Radiol. 2004; 14: 1371-1379.
  • 19
    Booser DJ, Hortobagyi GN. Treatment of locally advanced breast cancer. Semin Oncol. 1992; 19: 278-285.
  • 20
    Bonadonna G, Valagussa P. Primary chemotherapy in operable breast cancer. Semin Oncol. 1996; 23: 464-474.
  • 21
    Gralow JR. Preoperative therapy in invasive breast cancer: reviewing the state of the science and exploring new research directions. J Clin Oncol. 2008; 26: 696-697.
  • 22
    Prati R, Minami CA, Gornbein JA, Debruhl N, Chung D, Chang HR. Accuracy of clinical evaluation of locally advanced breast cancer in patients receiving neoadjuvant chemotherapy. Cancer. 2009; 115: 1194-1202.
  • 23
    Buzdar AU, Ibrahim NK, Francis D, et al. Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer. J Clin Oncol. 2005; 23: 3676-3685.
  • 24
    Fisher B, Bryant J, Wolmark N, et al. Effect of preoperative chemotherapy on the outcome of women with operable breast cancer. J Clin Oncol. 1998; 16: 2672-2685.
  • 25
    Wolmark N, Wang J, Mamounas E, Bryant J, Fisher B. Preoperative chemotherapy in patients with operable breast cancer: 9-year results from National Surgical Adjuvant Breast and Bowel Project B-18. J Natl Cancer Inst Monogr. 2001; 30: 96-102.
  • 26
    Ring AE, Smith IE, Ashley S, et al. Oestrogen receptor status, pathological complete response and prognosis in patients receiving neoadjuvant chemotherapy for early breast cancer. Br J Cancer. 2004; 91: 2012-2017.
  • 27
    Buzdar AU, Valero V, Theriault R, et al. Pathological complete response to chemotherapy is related to hormone receptor status [abstract]. Breast Cancer Res Treat. 2003; 82( suppl 1): S69. Abstract 302.
  • 28
    Bonnefoi H, Zaman K, Koch KM, et al. Lapatax: a phase I study of neoadjuvant lapatinib combined with docetaxel in Her2/neu overexpressing breast cancer (BC). EORTC protocol 10054 [abstract]. Cancer Res. 2009; 69( 2 suppl): 342s. Abstract 5112.
  • 29
    Chia S, Bryce C, Pansegrau G, et al. Phase II trial of neoadjuvant chemotherapy of sequential FEC100 followed by docetaxel, carboplatin and trastuzumab (TCH) for HER-2 over-expressing locally advanced breast cancer (LABC): a multi-centre study from British Columbia [abstract]. Cancer Res. 2009; 69( 2 suppl): 344s. Abstract 5118.
  • 30
    Wildiers H, Neven P, Christiaens M-R, et al. Multicenter phase II study of neoadjuvant capecitabine (X), docetaxel (T) ± trastuzumab (H) for patients (pts) with locally advanced breast cancer (LABC): final analysis [abstract]. Cancer Res. 2009; 69( 2 suppl): 343s. Abstract 5115.
  • 31
    Buzdar AU, Valero V, Ibrahim NK, et al. Neoadjuvant therapy with paclitaxel followed by 5-fluorouracil, epirubicin, and cyclophosphamide chemotherapy and concurrent trastuzumab in human epidermal growth factor receptor 2-positive operable breast cancer: an update of the initial randomized study population and data of additional patients treated with the same regimen. Clin Cancer Res. 2007; 13: 228-233.
  • 32
    Burstein HJ, Harris LN, Gelman R, et al. Preoperative therapy with trastuzumab and paclitaxel followed by sequential adjuvant doxorubicin/cyclophosphamide for HER2 overexpressing stage II or III breast cancer: a pilot study. J Clin Oncol. 2003; 21: 46-53.
  • 33
    Harris L, Burstein HJ, Gelman R, et al. Preoperative trastuzumab and vinorelbine (HN) is a highly active, well-tolerated regimen for HER2 3+/FISH+ stage II/III breast cancer [abstract]. Proc Am Soc Clin Oncol. 2003; 22. Abstract 86.
  • 34
    Hurley J, Doliny P, Silva O, et al. Neoadjuvant Herceptin/taxotere/cisplatin in the treatment of locally advanced and inflammatory breast cancer [abstract]. Proc Am Soc Clin Oncol. 2002; 21: 50a Abstract 196.
  • 35
    Jahanzeb M, Brufsky A, Erban J, Lewis D, Limentani S. Dose-dense neoadjuvant treatment of women with breast cancer utilizing docetaxel, vinorelbine and trastuzumab with growth factor support [abstract]. J Clin Oncol. 2005; 23( 16S): 26s. Abstract 591.
  • 36
    Gianni L, Semiglazov V, Manikhas GM, et al. Neoadjuvant trastuzumab in locally advanced breast cancer (NOAH): antitumor and safety analysis [abstract]. J Clin Oncol. 2007; 25( 18S): 10s. Abstract 532.
  • 37
    Livasy C, Carey L, DeMichele A, et al. Influence of anthracycline- and taxane-based neoadjuvant chemotherapy on tumor HER2 protein expression in locally advanced breast cancers: results from the I-SPY trial (CALGB 150007/150012 & ACRIN 6657) [abstract]. Cancer Res. 2009; 69( 2 suppl): 97s. Abstract 703.
  • 38
    Masuda N, Nakayama T, Matsunami N, et al. Phase II trial of neoadjuvant 5-fluorouracil, epirubicin and cyclophosphamide (FEC100) followed by weekly paclitaxel and trastuzumab (PH) for HER2 positive breast cancer (Kinki Multidisciplinary Breast Oncology Group; KMBOG-0402) [abstract]. Cancer Res. 2009; 69( 2 suppl): 256s. Abstract 3160.
  • 39
    Mittendorf EA, Esteva FJ, Wu Y, et al. Determination of HER2 status in patients achieving less than a pathologic complete response following neoadjuvant therapy with combination chemotherapy plus trastuzumab [abstract]. Paper presented at: 2008 Breast Cancer Symposium; September 5-7, 2008; Washington, DC. Abstract 150.
  • 40
    von Minckwitz G, Rezai M, Loibl S, et al. Effect of trastuzumab on pathologic complete response rate of neoadjuvant EC-docetaxel treatment in HER2-overexpressing breast cancer: results of the phase III GeparQuattro study [abstract]. Paper presented at: 2008 Breast Cancer Symposium; September 5-7, 2008; Washington, DC. Abstract 226.
  • 41
    Raefsky E, Castillo R, Lahiry A, et al. Phase II study of neoadjuvant bevacizumab and trastuzumab administered with albumin-bound paclitaxel (NAB paclitaxel) and carboplatin in HER2+ locally advanced breast cancer [abstract]. J Clin Oncol. 2008; 26( 15S): 37s. Abstract 627.
  • 42
    Paz IB, Lau S, Garberoglio C, et al. NAB-paclitaxel and carboplatin with or without trastuzumab (trast) as part of neoadjuvant chemotherapy (NCT) in patients (pts) with stage II-III breast cancer (BC) [abstract]. J Clin Oncol. 2008; 26( 15S): 22s. Abstract 567.
  • 43
    Chang HR, Slamon D, Prati R, et al. A phase II study of neoadjuvant docetaxel/carboplatin with or without trastuzumab in locally advanced breast cancer: response and cardiotoxicity [abstract]. J Clin Oncol. 2006; 24( 18S): 569s. Abstract 10515.
  • 44
    Chang HR, Slamon D, Gornbein JA, Chung D. Preferential pathologic complete response (pCR) by triple-negative (−) breast cancer to neoadjuvant docetaxel (T) and carboplatin (C) [abstract]. J Clin Oncol. 2008; 26( 18S): 31s. Abstract 604.
  • 45
    National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Breast Cancer v. 2.2008. Available at: http://www.nccn.org/professionals/physician_gls/PDF/breast.pdf. Accessed November 1, 2008.
  • 46
    Gianni L, Eiermann W, Semiglazov V, et al. Neoadjuvant trastuzumab in patients with HER2-positive locally advanced breast cancer: primary efficacy analysis of the NOAH trial [abstract]. Cancer Res. 2009; 69( 2 suppl). Abstract 31.
  • 47
    Gianni L, Eiermann W, Pusztai, et al. Biomarkers as potential predictors of pathologic complete response (pCR) in the NOAH trial of neoadjuvant trastuzumab in patients (pts) with HER2-positive locally advanced breast cancer (LABC) [abstract]. J Clin Oncol. 2008; 26( 15S): 8s. Abstract 504.
  • 48
    Guarneri V, Frassoldati A, Cagossi K, et al. CHER LOB trial: preoperative chemotherapy plus trastuzumab, lapatinib or both in HER2-positive operable breast cancer—safety report as per Independent Data Monitoring Committee (IDMC) and preliminary activity data [abstract]. J Clin Oncol. 2008; 26( 15S): 26s. Abstract 580.
  • 49
    Grande E, Sanchez-Munoz A, Garcia-Tapiador A, et al. Efficacy and safety of neoadjuvant chemotherapy of sequential doublets and dose dense plus trastuzumab in HER2-positive locally advanced breast cancer patients [abstract]. J Clin Oncol. 2007; 25( 18S): 601s. Abstract 11089.
  • 50
    Iovino F, Ferraraccio F, Orditura M, et al. Serum vascular endothelial growth factor (VEGF) levels correlate with tumor VEGF and p53 overexpression in endocrine positive primary breast cancer. Cancer Invest. 2008; 26: 250-255.
  • 51
    Mylona E, Alexandrou P, Giannopoulou I, et al. The prognostic value of vascular endothelial growth factors (VEGFs)-A and -B and their receptor, VEGFR-1, in invasive breast carcinoma. Gynecol Oncol. 2007; 104: 557-563.
  • 52
    Yen L, You XL, Al Moustafa AE, et al. Heregulin selectively upregulates vascular endothelial growth factor secretion in cancer cells and stimulates angiogenesis. Oncogene. 2000; 19: 3460-3469.
  • 53
    Tsai PW, Shiah SG, Lin MT, et al. Up-regulation of vascular endothelial growth factor C in breast cancer cells by heregulin-h1. A critical role of p38/nuclear factor-nB signaling pathway. J Biol Chem. 2003; 278: 5750-5759.
  • 54
    Pegram MD, Reese DM. Combined biological therapy of breast cancer using monoclonal antibodies directed against HER2/neu protein and vascular endothelial growth factor. Semin Oncol. 2002; 29( 3 suppl 11): 29-37.
  • 55
    Le XF, Mao W, Lu C, et al. Specific blockade of VEGF and HER2 pathways results in greater growth inhibition of breast cancer xenografts that overexpress HER2. Cell Cycle. 2008; 7: 3747-3758.
  • 56
    Mehta RS, Shubbert T, Hsiang D, Kong K. Phase II study of neoadjuvant biweekly doxorubicin and cyclophosphamide (AC) with GM-CSF followed by weekly paclitaxel, carboplatin ± trastuzumab (TC±H) in the treatment of breast cancer (BC) [abstract]. J Clin Oncol. 2005; 23( 16S): 84s. Abstract 826.
  • 57
    Mehta RS, Shubbert T, Kong K. Paclitaxel, carboplatin and trastuzumab (TCH) achieves high pathological complete remission rate after in vivo response directed 2-4 cycles of doxorubicin and cyclophosphamide (AC) in breast cancer patients [abstract]. J Clin Oncol. 2006; 24( 18S): 574s. Abstract 10583.
  • 58
    Ro J, Park IH, Lee KS, et al. Comparable efficacies between premenopausal and postmenopausal metastatic breast cancer patients by letrozole with and without goserelin as first line hormone therapy: a phase II parallel group study [abstract]. Cancer Res. 2009; 69( 2 suppl): 399s. Abstract 6134.
  • 59
    Rastogi P, Jeong J, Geyer CE, et al. Five-year update of cardiac dysfunction on NSABP B-31, a randomized trial of sequential doxorubicin/cyclophosphamide (AC)-paclitaxel (T) compared to AC-T with trastuzumab(H) [abstract]. Proc Am Soc Clin Oncol. 2007; 25( 18S): 6s. Abstract LBA513.
  • 60
    Perez EA, Suman VJ, Davidson NE, et al. Cardiac safety analysis of doxorubicin and cyclophosphamide followed by paclitaxel with or without trastuzumab in the North Central Cancer Treatment Group N9831 adjuvant breast cancer trial. J Clin Oncol. 2008; 26: 1231-1238.
  • 61
    Breast International Group/North Central Cancer Treatment Group. Neo-Adjuvant Lapatinib and/or Trastuzumab Treatment Optimisation Trial. Available at: http://alttotrials.com/neoaltto.php. Accessed November 1, 2008.
  • 62
    National Surgical Adjuvant Breast and Bowel Project. NSABP Clinical Trials Overview. Available at: http://www.nsabp.pitt.edu/B-41.asp. Accessed November 1, 2008.
  • 63
    American College of Surgeons/National Cancer Institute. Combination Chemotherapy and Paclitaxel Plus Trastuzumab in Treating Women With Palpable Breast Cancer That Can Be Removed by Surgery. Available at: http://clinicaltrials.gov/ct2/show/NCT00513292. Accessed November 1, 2008.
  • 64
    Fisher ER, Wang J, Bryant J, et al. Pathobiology of preoperative chemotherapy: findings from the National Surgical Adjuvant Breast and Bowel Project (NSABP) protocol B-18. Cancer. 2002; 95: 681-695.
  • 65
    Neuman H, Carey LA, Ollila DW, et al. Axillary lymph node count is lower after neoadjuvant chemotherapy. Am J Surg. 2006; 191: 830-831.
  • 66
    Yamamoto M, Mehta RS, Baick CH, et al. The predictive value of sentinel lymph node biopsy in locally advanced breast cancer patients who have undergone neoadjuvant chemotherapy. Am Surg. 2007; 73: 977-980.
  • 67
    Mehta RS, Schubbert T, Kong K. Trastuzumab in inflammatory breast cancer. Ann Oncol. 2008; 19: 1815-1817.
  • 68
    Yen TW, Hunt KK, Ross MI, et al. Predictors of invasive breast cancer in patients with an initial diagnosis of ductal carcinoma in situ: a guide to selective use of sentinel lymph node biopsy in management of ductal carcinoma in situ. J Am Coll Surg. 2005; 200: 516-526.